Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $17,445.00 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 1,163 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $15.00, for a total transaction of $17,445.00. Following the transaction, the insider owned 133,087 shares in the company, valued at approximately $1,996,305. The trade was a 0.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

KalVista Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ:KALV opened at $15.83 on Friday. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The stock has a market cap of $800.21 million, a price-to-earnings ratio of -4.01 and a beta of -0.19. The company has a 50 day moving average of $15.50 and a 200-day moving average of $13.89. KalVista Pharmaceuticals, Inc. has a one year low of $9.23 and a one year high of $19.00.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of KalVista Pharmaceuticals by 3.7% during the third quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock worth $30,464,000 after purchasing an additional 88,720 shares during the period. Tudor Investment Corp ET AL bought a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $24,360,000. State Street Corp raised its holdings in KalVista Pharmaceuticals by 21.3% during the 4th quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock worth $30,874,000 after buying an additional 336,195 shares during the period. Vestal Point Capital LP lifted its stake in KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after buying an additional 1,140,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC boosted its holdings in shares of KalVista Pharmaceuticals by 155.5% in the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after buying an additional 1,055,940 shares during the period.

Analyst Upgrades and Downgrades

KALV has been the topic of several recent research reports. Citizens Jmp reduced their price target on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Tuesday, November 11th. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Finally, Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $29.40.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.